Pluri (NASDAQ:PLUR) Director Alexandre Weinstein Manieu Purchases 833,334 Shares of Stock

Pluri Inc. (NASDAQ:PLUR) Director Alexandre Weinstein Manieu purchased 833,334 shares of the firm’s stock in a transaction dated Friday, October 23rd. The stock was acquired at an average cost of $1.50 per share, with a total value of $1,250,001.00. Following the purchase, the director owned 2,083,334 shares of the company’s stock, valued at approximately $3,125,001. This represents a 66.67% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Pluri Stock Performance

Shares of PLUR opened at $1.19 on Wednesday. Pluri Inc. has a one year low of $0.85 and a one year high of $4.87. The stock’s fifty day moving average is $1.19 and its 200-day moving average is $2.41. The firm has a market capitalization of $15.01 million, a price-to-earnings ratio of -0.49 and a beta of 0.69.

Pluri (NASDAQ:PLUR) last posted its quarterly earnings data on Thursday, September 10th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.12. The company had revenue of $0.34 million during the quarter, compared to analyst estimates of $0.66 million.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Pluri Company Profile

Pluri Inc is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification.

Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.